Edition:
United Kingdom

People: Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

0.35USD
18 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.35
Open
--
Day's High
--
Day's Low
--
Volume
44,829
Avg. Vol
191,257
52-wk High
$14.55
52-wk Low
$0.26

Berlin, Kenneth 

Mr. Kenneth A. Berlin is President, Chief Executive Officer, Director of the company. He joins Advaxis from Rosetta Genomics, where since 2009 he was President and Chief Executive Officer. Prior to Rosetta Genomics, Mr. Berlin was Worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company. Mr. Berlin joined Johnson & Johnson in 1994, and served as corporate counsel for six years. He led and participated on the legal team that oversaw several mergers, acquisitions, divestitures and commercial transactions. He then held positions of increasing responsibility within Johnson & Johnson and a number of its subsidiary companies. From 2001 until 2004 he served as Vice President, Licensing and New Business Development in the pharmaceuticals group, and from 2004 until 2007 served as Worldwide Vice President, Franchise Development, Ortho-Clinical Diagnostics.

Basic Compensation

Total Annual Compensation, USD 427,353
Restricted Stock Award, USD 405,000
Long-Term Incentive Plans, USD --
All Other, USD 965,103
Fiscal Year Total, USD 1,797,460

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Sidransky

2,020,800

Kenneth Berlin

1,797,460

James Patton

--

Molly Henderson

521,871

Roni Appel

144,615

Samir Khleif

--
As Of  31 Oct 2018